Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Genesis. 2010 Jul;48(7):446–451. doi: 10.1002/dvg.20635

FIG. 2.

FIG. 2

(a) Schematic diagram of the CMV-LoxP-Stop-LoxP-LacZ (CMV-LSL-LacZ) construct. (b) The podocin-iCre-ERT2 construct was tested in podocytes in vitro by using CMV-LSL-LacZ, a floxed LacZ reporter. Podocytes were exposed to tamoxifen for 16 h and evaluated by β-gal staining. (I) control nontransfected podocytes, (II) transfected podocytes with podocin-iCre-ERT2 construct, (III) podocytes transfected with both podocin-iCre-ERT2 and LacZ floxed constructs but only exposed to vehicle for 16 h (IV) podocytes transfected with both constructs and exposed to tamoxifen (100 nM) for 16 h. β-gal activation is manifested by bright blue staining.